Transcript Highlights:

• And this is a drug that is legal, right?
• In the drug supply, like it's, so I guess we just come out opposed to straight up scheduling of xylazine
• So how do you say, okay, Schedule 3, you think they care about Schedule 3?
• Is there a power level utilized by, you know, like they did with other drugs, you know, legal drugs?
• the drug is.

Keywords: 995, all

Summary: The working group on best practices for oversight and enforcement met for its first session and focused on xylazine, including its legal veterinary uses, its appearance in the illicit drug supply, and whether it should be classified as a controlled substance. Members discussed the distinction between pharmaceutical-grade and non-pharmaceutical-grade xylazine, the role of international/illicit sourcing, and the limits of state-level regulation if the substance is already being added to fentanyl or other drugs outside the Commonwealth. The Department of Public Health representative summarized the agency’s view that scheduling xylazine could follow the “ironclad law of prohibition” and push the market toward other, potentially worse substances, and said DPH opposed straight scheduling in favor of education, support, and harm-reduction approaches. Veterinary members explained how xylazine is used in large-animal and research settings, why it is useful, and why federal-style scheduling could create practical burdens for veterinarians who work in the field. They also described reversal agents such as yohimbine and atipamezole (Antisedan), and noted that xylazine is not commonly used in small-animal practice. Several members raised questions about how much xylazine is actually used legally in Massachusetts, whether boards of pharmacy or distributors could provide useful data, and what other states have done. Arizona and Florida were mentioned as possible examples for further research, along with the need to examine stakeholder opposition and any effects on legitimate veterinary practice. The group agreed to divide into two subgroups: one focused on oversight and regulation of production/distribution, and another on whether xylazine should be classified as a controlled substance and what penalties, if any, should apply. Staff said they would circulate notes, a draft PowerPoint template, and a shared folder, with members asked to submit materials by December 2, draft materials due December 4, and final approval by December 9 ahead of the next public meeting on December 11. The meeting ended with a motion to adjourn, a second, and unanimous closure.

Transcript Highlights:

• Um, so we're looking to mandate the drug as a Schedule III controlled substance.
• Um, so we're looking to mandate the drug as a Schedule III controlled substance.
• as a schedule mandate the drug as a schedule 3-controlled<00:45:29.119><c> substance.
• Rather than classifying this drug in Schedule 1 due to its unaccepted human use, classification in Schedule
• Rather than classifying this drug in Schedule 1 due to its unaccepted human use, classification in Schedule

Keywords: 1191, senate, all

Transcript Highlights:

• 3 now like any other Schedule 3 drug, right?
• 3 now like any other Schedule 3 drug, right?
• 3 now like any other Schedule 3 drug, right?
• 3 now like any other Schedule 3 drug, right?
• </c> schedule three drug right? schedule three drug right?

Keywords: 912, senate, all

Summary: The committee heard testimony on SB 3025, relating to medical debt, with multiple organizations and individuals, including the Office of Wellness and Resilience, Healthcare Association of Hawaii, Queens Health Systems, the American Cancer Society Cancer Action Network, Aloha Care, Hawaii Health and Harm Reduction, Hawaii Data Collaborative, and Hawaii Appleseed, all speaking in support. No opposition was heard, and the member present had no questions. The committee then took up SB 3199, which would establish a mental health emerging therapies task force. Testimony was overwhelmingly in support, with speakers including veterans, clinicians, researchers, and advocacy groups describing personal experiences with PTSD, depression, traumatic brain injury, and treatment-resistant conditions, and arguing that Hawaii should prepare for regulated access to emerging therapies such as MDMA, psilocybin, ketamine, and ibogaine. The Department of Health and some medical organizations provided comments, and one opposition witness was called but not present. The chair noted broad support, especially from veterans, and no vote was taken during the excerpt. The final measure discussed was SB 3324, relating to Medicaid. The Department of Human Services, Department of Health, Hawaii State Council on Developmental Disabilities, Hawaii Disability Rights Center, Aloha Care, and numerous care-provider and aging/disability organizations testified in support, while one witness was in opposition and several others offered comments. The discussion then moved to SB 2563, relating to homelessness, where the Department of the Attorney General offered comments on specific sections and recommended adopting suggested amendments if the bill proceeds. Additional testimony on SB 2563 began with support from several individuals, including Shelby Pikachu, who emphasized the severity of homelessness and related social problems in the community.

Transcript Highlights:

• I drugs.
• Categorized as Schedule I drugs, so this was a decision by our DEA that was not based on any scientific
• I drug.
• So this was a decision by our DEA. categorized as Schedule 1 drug, so this was a decision by our DEA
• SRI is already a federally approved manufacturer of psilocybin and several other Schedule I drugs.

Summary: The Senate Ad Hoc Committee on Access to Breakthrough Mental Health Therapies held an informational hearing focused on psychedelic-assisted treatments for PTSD, depression, addiction, and related conditions, especially for veterans, first responders, and firefighters. The chair framed the issue as a response to long-standing barriers created by Schedule I restrictions and stigma, emphasizing that the committee was looking at supervised clinical use rather than take-home drugs. Members discussed the growing number of state psychedelic policy proposals, the federal breakthrough therapy pathway, and the idea of Arizona preparing for FDA approval and possibly sending correspondence to federal officials in support of expanded access and Right to Try implementation. Witnesses included retired Army Special Forces Master Sgt. Alan Mullen, who described participating in an ibogaine study for PTSD/TBI and said the treatment, combined with preparation and integration support, helped him confront trauma and showed promise under strict medical monitoring. Dr. Sue Sisley of Scottsdale Research Institute testified that her team is conducting FDA-controlled psychedelic trials, including psilocybin research funded by Arizona, and argued that these therapies can produce major symptom relief with limited doses when delivered in controlled settings. She also urged the legislature to help remove barriers to research and access, including support for Right to Try and possible federal action to allow controlled-substance access. Dan Freiberg of the Professional Fire Fighters of Arizona said firefighters face chronic mental health exposure and often lack effective options beyond traditional therapy or, in some cases, ketamine, and he supported any safe, effective treatment that could help members return to work and reduce suicide risk. Dr. Chung Trin, a mental health physician and trial investigator, explained the FDA breakthrough designation process, said several psychedelic treatments are in late-stage review, and stressed the need for Arizona to build clinical infrastructure so patients can access approved therapies quickly and safely once federal approval occurs. Committee members asked about safety, addiction potential, suicide risk, costs, patents, and whether natural versus synthetic versions of compounds like psilocybin would be available; the hearing ended with general support for continued research, possible legislative correspondence to federal officials, and no formal vote or bill action taken.

Transcript Highlights:

• This bill makes xylazine a Schedule III drug. It's the lowest level we can do.
• And a lot of people think that by scheduling these types of chemicals and these drugs, the goal isn't
• And a lot of people think that by scheduling these types of chemicals and these drugs, the goal isn't
• And I am not proposing a Schedule I drug, as they both know.
• And I have elected the lowest level of schedule possible for a lethal drug.

Summary: The committee heard several public safety bills, with testimony split between supporters who framed the measures as targeted fixes and opponents who warned about overcriminalization and unintended consequences. SB 701, by Senator Wahab, drew support from law enforcement and local government groups, who said state law lacks a tool to address the conduct at issue; the ACLU opposed it as duplicative of existing law, while public defenders said they may withdraw opposition after amendments. Because there was no quorum at that point, the bill was held open without a vote. SB 834, by Senator DeRazzo, was presented as a technical cleanup bill to improve California’s automatic record clearance system by preventing outdated “pending” charges from blocking relief, requiring local court records to match DOJ records, and creating a way for people to obtain proof of relief. It received broad support from criminal justice reform and defense organizations, with no opposition, and the chair indicated support, but no final action was taken during the hearing. SB 248, by Senator Rubio, would require DOJ to send new gun purchasers educational materials during the waiting period about safe storage, suicide prevention, domestic violence, and related resources; supporters called it common-sense education, while one opponent argued the information is already available. The committee voted the bill out on a due-pass motion to Appropriations, but it remained on call pending one additional vote. Senator Rubio’s SB 19, the Safe Schools and Places of Worship Act, would create a new offense for credible threats against schools or houses of worship even when no specific individual is named. Supporters, including law enforcement and Jewish community advocates, said current law leaves a loophole and that the bill would help prevent panic and resource-draining lockdowns; opponents from civil liberties and youth justice groups argued existing law already covers threats and that the bill would worsen the school-to-prison pipeline. After a motion and second, the committee voted due pass to Appropriations, with the measure also left on call. Later, SB 759 by Senator Archuleta, prompted by the killing of Whittier Officer Keith Boyer, would require a court hearing after a third supervision violation or new offense for people on post-release community supervision; supporters said it adds accountability, while opponents said it removes probation discretion and could increase jail and court burdens. The bill passed due pass to Appropriations and was reported as passing. The committee also heard SB 6 by Senator Ashby, which would schedule xylazine as a controlled substance while preserving veterinary use. Supporters, including veterinarians, law enforcement, and a parent who lost a son to a drug-related death, said the drug is increasingly present in fentanyl mixtures and needs to be controlled; opponents from drug policy and civil liberties groups argued scheduling would criminalize users, hinder research, and repeat failed drug-war policies. After extensive debate, the committee voted the bill out due pass to Appropriations, and it passed. Finally, SB 11, the AI Abuse Protection Act, was introduced to regulate AI-generated voice, image, and video replicas, with supporters emphasizing protection against deepfakes and nonconsensual images; the California Chamber of Commerce opposed unless amended, seeking narrower definitions and limits on consumer warnings. The hearing ended while SB 11 was still under discussion, with no final vote reflected in the transcript.

Transcript Highlights:

• But I am afraid, from the scientific standpoint, scheduling it as Schedule I, that will disincentivize
• scheduled narcotics like cocaine and heroin.
• our Drug Medi-Cal program and state-designated alcohol and other drug programs more accessible.
• When FDA took steps in July of 2025 to initiate the scheduling of the synthetic drug 7-OH, the agency
• Showing why it shouldn’t be scheduled.

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful for consumption, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. The hearing was framed as part of ongoing legislative work, including a future review of AB 1088, and members emphasized the need to weigh potential benefits against risks and consider whether stronger safeguards are needed. Expert testimony from a toxicology professor and several public health and medical officials described kratom as a plant with multiple alkaloids, with 7-OH identified as the more potent opioid-like compound associated with tolerance, dependence, withdrawal, and respiratory depression. CDPH reported 362 kratom-related overdose deaths in California from 2019 to 2023 and 15 deaths involving 7-OH, while Los Angeles County officials described unexplained deaths in young adults that led them to expand toxicology testing and identify 7-OH as a common factor. County and state public health representatives said they have issued advisories, contacted retailers, removed products from shelves, and taken enforcement actions, but they stressed that local enforcement is patchy, under-resourced, and limited by unclear jurisdiction and lack of testing capacity. Medical witnesses said patients are presenting with 7-OH dependence and withdrawal in ways similar to fentanyl-related cases, sometimes requiring buprenorphine, methadone, or repeated naloxone. They argued that unregulated retail sales and misleading marketing make the products especially risky, and that a statewide framework would be more effective than a patchwork of local ordinances. Some officials said the safest current policy is to keep kratom and 7-OH unlawful for consumption, while others said any new regulation would need resources, packaging rules, and clearer authority for enforcement. Industry and consumer advocates urged the committee to distinguish natural kratom leaf from concentrated or synthetic 7-OH products. They argued that kratom leaf has long-standing use, that 7-OH should be targeted rather than the whole plant, and that regulation should focus on age limits, labeling, testing, serving-size caps, and restrictions on adulterated products rather than prohibition. Several speakers warned that bans could push demand to the black market and reduce access for people using the products for pain relief or harm reduction, while critics of the industry said the products are being marketed deceptively and that more comprehensive regulation is needed.

Transcript Highlights:

• So Schedule 1 and 2 are the most serious drugs that we find being given to our minors.
• And then we did schedule one or two to get the other drugs. We included.
• One of my big concerns is you have in here Schedule 3 drugs and.
• A Schedule 3 drug is also medical cannabis, and that is.
• It's just Schedule 1 and Schedule 2 drugs. And methamphetamine.

Keywords: 996, all

Transcript Highlights:

• </c> exposure to street drugs exposure to street drugs the<00:24:59.120><c> bill</c><00:24:59.360><c>
• When you compare a drug-free zone to schools, to a drug-free zone for hospitals, it does definitely make
• My second question has to do with the Schedule IV and V drugs.
• My second question has to do with the Schedule IV and V drugs.
• </c> selling drugs using drugs on Hospital selling drugs using drugs on Hospital grounds<00:43:56.520

Keywords: Meeting Start: 00:00:00 Roll Call: 00:00:09 SB 64: 00:01:20 SB 73: 00:05:33 HB 662: 00:09:40 HB 320: 00:20:17, 958, all

Summary: The House Judiciary Committee met with a quorum and first approved Senate Bill 64, as amended, on a 14-0 vote. The bill was described as a copper theft prevention measure aimed at protecting key infrastructure assets, including telecommunications and electrical highway infrastructure. Testimony in support came from Senator Brandon Storm and representatives from Charter Communications and law enforcement, who said copper theft and related vandalism are damaging fiber and other infrastructure across the state. A committee substitute was adopted before the vote. The committee then considered Senate Bill 73, relating to sexual extortion. Senator Julie Rocky Adams and Kentucky Youth Advocates testified that sextortion is a fast-growing crime against children and that the bill would make sexual extortion a felony, create civil remedies for victims, and require school-based education and resources. The bill passed 15-0 and was reported favorably for floor consideration. House Bill 662, relating to personally identifiable information, was also approved after discussion and a committee substitute. Representative John Blanton said the bill would help protect judges and certain medical review personnel from public disclosure of personal information while preserving provider access needed for appeals and communications. The Kentucky Medical Association supported the concept but stressed the need to preserve provider-facing information so doctors can conduct peer-to-peer reviews and appeals. The bill passed 15-0 with one pass vote. House Bill 320, relating to controlled substances on hospital property, was taken up for discussion only and no vote was taken. Representative Mike Klein and a St. Elizabeth nurse testified that hospitals are seeing illicit drug use and trafficking on campus and argued for a drug-free zone to protect staff, patients, and visitors. Committee members raised concerns about how the bill would apply to unconscious overdose patients, lawfully prescribed medications, emergency situations, and whether possession should be treated differently from trafficking. The chair ruled a motion out of order because the item was for discussion only, and the bill remained under consideration.

Transcript Highlights:

• I drugs.
• Categorized as Schedule I drugs, so this was a decision by our DEA that was not based on any scientific
• Categorized as Schedule I drugs, so this was a decision by our DEA that was not based on any scientific
• SRI is already a federally approved manufacturer of psilocybin and several other Schedule I drugs.
• drugs.

Keywords: 1182, all

Summary: The Senate Ad Hoc Committee on Access to Breakthrough Mental Health Therapies met to discuss psychedelic-assisted treatments for serious mental health conditions, with a focus on psilocybin, ibogaine, MDMA, and related compounds. The chair framed the issue as a clinical and access problem for veterans, first responders, and others with PTSD, depression, TBI, addiction, and suicidal ideation, emphasizing that these therapies are intended for supervised medical settings rather than take-home use. Members reviewed research claims and policy trends, including FDA breakthrough therapy designations, state-level psychedelic legislation, and the role of Arizona’s right-to-try law in expanding access once federal approval is in place. Testimony came from Alan Mullen, a retired Army Special Forces veteran, who described his PTSD/TBI history and said ibogaine treatment helped him confront trauma and showed promise in reducing symptoms under strict medical monitoring. Dr. Sue Cisley of Scottsdale Research Institute described ongoing FDA-controlled trials in Arizona, said current medications often fail high-need patients, and urged removal of research barriers and preparation for right-to-try and expanded access. Dan Freiberg of the Professional Firefighters of Arizona said firefighters face chronic exposure to trauma, often rely on alcohol or other coping mechanisms, and need effective alternatives beyond traditional therapy. Dr. Chung Trin discussed late-stage psychedelic trials, the FDA breakthrough pathway, safety oversight, and the need for state readiness when approvals occur. Committee members asked about how the treatments work, whether they require psychotherapy support, safety concerns including suicidality and black-market abuse, patenting and synthetic versus natural versions, and costs compared with ketamine and other treatments. Witnesses said the therapies are administered with extensive screening, monitoring, and integration support, and argued that addiction potential appears low under medical supervision. The discussion ended with interest in sending correspondence to federal officials to support right-to-try cooperation and in continuing the research and policy work; no formal vote or action was taken in the portion provided.

Transcript Highlights:

• But I am afraid, from the scientific standpoint, scheduling it as Schedule I would disincentivize a lot
• scheduled narcotics like cocaine and heroin.
• We're focused on making our Drug Medi-Cal program and state-designated alcohol and other drug programs
• When FDA took steps in July of 2025 to initiate the scheduling of the synthetic drug 7-OH, the agency
• Showing why it shouldn't be scheduled.

Keywords: 987, senate, all

Transcript Highlights:

• But I am afraid from, if you're asking me from the scientific standpoint, scheduling it as Schedule I
• scheduled narcotics like cocaine and heroin.
• our Drug Medi-Cal program and state-designated alcohol and other drug programs more accessible.
• When FDA took steps in July of 2025 to initiate the scheduling of the synthetic drug 7-OH, the agency
• Showing why it shouldn't be scheduled.

Summary: The committee held an informational hearing on kratom and 7-hydroxymitragynine (7-OH), focusing on public health risks, overdose deaths, and regulatory gaps in California. The chair opened by noting that FDA and CDPH consider kratom and 7-OH products unlawful, yet they remain widely sold in smoke shops, vape stores, gas stations, and convenience stores. Members referenced AB 1088, which would be considered later, and said the hearing was intended to clarify the science, medical perspective, and whether stronger safeguards are needed. The first panel featured a toxicology expert, state and local public health officials, an emergency/addiction physician, a medical examiner, and county health representatives. Witnesses from CDPH and Los Angeles County described rising deaths and enforcement actions, including statewide advisories, retailer letters, and product removals from manufacturers, wholesalers, and retailers. Medical testimony emphasized that 7-OH acts much more like an opioid than traditional kratom leaf, can cause dependence, withdrawal, and respiratory depression, and may require naloxone, buprenorphine, or methadone in overdose or withdrawal cases. Local officials said enforcement is difficult because packaging is inconsistent, testing capacity is limited, and counties lack resources and statewide infrastructure; they generally favored a centralized state framework if regulation is pursued. Committee members asked about testing, age restrictions, scheduling, and whether a distinction between kratom and 7-OH could be enforced. Witnesses said forensic labs can potentially test for 7-OH but validated assays are not routine, emergency departments cannot readily distinguish exposures, and local health departments do not have the lab capacity to verify product labels. Several officials warned that a ban or abrupt scheduling could push products into the black market and discourage research, while others argued that current prohibition and enforcement are the most protective approach because legalization or age-limited regulation could create confusion about legality and safety. The second panel included kratom and 7-OH advocates and industry representatives, who argued that natural kratom leaf and concentrated or synthetic 7-OH are different products and should be regulated differently. They supported age-gating, labeling, testing, and packaging rules for kratom leaf while opposing a ban on the botanical. They said 7-OH is used by many adults for pain relief or harm reduction, and that prohibition would drive consumers to illicit markets and worsen harm. Committee members pressed them on whether 7-OH is more potent than kratom, the availability of testing, and whether any safe dose is known. The hearing ended without a vote or formal action, with the chair noting the issue will continue to be considered in future legislation.

Transcript Highlights:

• The House put an amendment on it requiring the insurance secretary to reassess the reimbursement schedule
• This is one of the four PBM package bills that deals with marketed generic drugs, net calculations, all

Bills: SCR12, HB221, HB509, HCR58, SB78, SB25, SB80, SB132, SB155, SB157, SB202, SB228, SB250, SB414, SB433, SB479, SB513, SCR9, SCR58, SB65, SB215, SB249, SB269, SB282, SB296, SB323, SB363, SB369, SB474, SB490, SB492, SB500, SB514, HCR32, HB17, HB41, HB73, HB223, HB244, HB759, HB906, HB966, HB1006, HB1009, HB1086, HB1107, HB1112, HB1215, HB1242, SB217, SB283, SB469, HB36, HB42, HB74, HB119, HB159, HB259, HB302, HB414, HB459, HB776, HB848, HB956, HB1017, HB1028, HB1095, SB208, SB312, SB382, SB389, HB210, HB258, HB359, HB368, HB468, HB552, HB732, HB784, HB870, HB953, HB1117, HB1236

Keywords: logging, recognition, John Keith, environment, safety, Mississippi River bridge, Trump Expressway, transportation, federal funding, Louisiana highways, injection wells, public hearing, geologic sequestration, environmental impact, public comment, Ascension Parish, state capitol, economic development, community partnership, celebration day

Summary: The Senate met with 29 members present, heard a prayer and national anthem presentation, and approved the journal without objection. The chamber then received multiple messages from the House on conference committee reports and concurrence actions, and took up a long calendar of Senate resolutions and House/Senate bills returned from the House with amendments. Several resolutions were adopted without objection, including commendations and requests for reports or studies, while others were left over or returned to the calendar. The Senate concurred in or adopted amendments on a series of bills covering registrar compensation (SB 25), broadband administration and reimbursement (SB 80), school safety master key boxes (SB 132), dental coverage for cancer treatment (SB 155), paid parental leave for educators (SB 157), election supervisor compensation days (SB 202), water utility service line replacement funding (SB 228), weight management services through the Office of Group Benefits (SB 250), medical debt protection (SB 414), Medicaid coverage of weight-loss medication (SB 443), and design-build authority for vertiport facilities (SB 513). It also adopted a House concurrent resolution urging backup motors for the St. Claude Avenue Bridge (HCR 32). One bill, SB 479 on removal of certain judges, had its amendments rejected and was sent to conference. The chamber then considered conference committee reports on several measures. Reports were adopted on SB 312 (labor organization dues and fees), SB 208 (veterans services and VA-related restrictions), SB 382 (workers’ compensation advisory council and reimbursement schedule timing), SB 389 (agent and athlete registration and fee review), and multiple House bills including HB 359 (party primary qualifying rules), HB 368 (New Orleans historic preservation lien procedures), HB 468 (wholesale residential real estate definitions), HB 552 (DWI-related responsive verdict language), HB 732 (motor vehicle fines/fees and hybrids), HB 870 and HB 1236 (pharmacy benefit manager and insurance provisions), and HB 1117 (prescription period issues). HB 210 on retroactivity was also adopted after debate. Several conference reports were temporarily passed over or returned to the calendar, including HB 953, and the Senate adjourned to reconvene the next morning for final work.

Transcript Highlights:

• The House put an amendment on it requiring the assistant secretary to reassess the reimbursement schedule
• This is one of the four PBM package bills that deals with marketed generic drugs, net calculations, and

Bills: SCR12, HB221, HB509, HCR58, SB78, SB25, SB80, SB132, SB155, SB157, SB202, SB228, SB250, SB414, SB433, SB479, SB513, SCR9, SCR58, SB65, SB215, SB249, SB269, SB282, SB296, SB323, SB363, SB369, SB474, SB490, SB492, SB500, SB514, HCR32, HB17, HB41, HB73, HB223, HB244, HB759, HB906, HB966, HB1006, HB1009, HB1086, HB1107, HB1112, HB1215, HB1242, SB217, SB283, SB469, HB36, HB42, HB74, HB119, HB159, HB259, HB302, HB414, HB459, HB776, HB848, HB956, HB1017, HB1028, HB1095, SB208, SB312, SB382, SB389, HB210, HB258, HB359, HB368, HB468, HB552, HB732, HB784, HB870, HB953, HB1117, HB1236

Keywords: logging, recognition, John Keith, environment, safety, Mississippi River bridge, Trump Expressway, transportation, federal funding, Louisiana highways, injection wells, public hearing, geologic sequestration, environmental impact, public comment, Ascension Parish, state capitol, economic development, community partnership, celebration day

Transcript Highlights:

• expensive, but we're required to have a drug being a preferred drug and covered a drug at least in all
• A legend drug is a drug that requires a prescription.
• A legend drug is a drug that requires a prescription.
• A legend drug is a drug that requires a prescription.
• </c> actual drug that's a prescription drug. actual drug that's a prescription drug.

Keywords: 1189, house, all

Transcript Highlights:

• of fentanyl-related substances under Schedule I, which is the strictest classification for drugs.
• of fentanyl-related substances under Schedule I, which is the strictest classification for drugs.
• one drugs will analogues as schedule one drugs will allow<02:55:02.840><c> our</c><02:55:03.120><c>
• Everyone says, well, if we schedule this as a Schedule I drug, then we're going to go right back to the
• </c> as a as a schedule one drug then we're as a as a schedule one drug then we're going<03:27:41.520

Keywords: U.S. House of Representatives Floor Proceedings on Thursday, February 6, 2025, 1012, house, all

Transcript Highlights:

• Because fentanyl itself has a proven medical use, it is considered a Schedule II drug.
• drugs placed on schedule system because drugs placed on schedule one<03:45:23.920><c> include</c><03
• The Halt Fentanyl Act will permanently schedule fentanyl-related substances as a class one drug.
• The Halt Fentanyl Act will permanently schedule fentanyl-related substances as a class one drug.
• The Halt Fentanyl Act will permanently schedule fentanyl-related substances as a class I drug.

Keywords: U.S. House of Representatives Floor Proceedings on Wednesday, June 11, 2025, 1012, house, all

Transcript Highlights:

• I to Schedule III.
• </c> support increased funding for drug support increased funding for drug recognition<00:45:51.920><
• III, my understanding, and again, I haven't looked at it in a long time, is that Schedule III drugs
• So if they move to Schedule III, you'll see more drugs like that on the pharmaceutical level.
• </c> to schedule 3, you'll see more drugs to schedule 3, you'll see more drugs like<01:58:56.000><c>

Bills: HB1974, HB1853, HB1973, HB1574, HB2619, HB1966, HB1643, HB1671, HB2558, HB1854, HB2173, HB1575, HB2229, HB1535, HB1978, HB2508, HB1549, HB2187, HB1550, HB1977, HB2314, HB1871, HB2319, HB1591, HB1858, HB1898, HB2372, HB1765, HB2012, HB1706, HB1962, HB1963, HB1975, HB2009, HB2083, HB2224, HB1877, HB1959, HB1626, HB1665, HB2488, HB2456, HB2548, HB2207, HB1832, HB2079, HB1985, HB1618, HB2486, HB2242, HB2045, HB1703, HB2236, HB2480, HB1976, HB2287, HB2288, HB1777, HB276, HB1660, HB1676, HB1605, HB1751, HB1967, HB2383, HB2340, HB1946, HB2268, HB1950, HB2156, HB2118, HB1859, HB1863, HB1996, HB2114, HB2423, HB2429, HB2475, HB2534, HB2545, HB1813, HB1941, HB2474, HB2583, HB1576, HB1886, HB1939, HB2540, HB2590, HB2000, HB2163, HB2386, HB1691, HB1680, HB2516, HB1993, HB2442, HB1510, HB1958, HB1692

Keywords: HB1974, hearing loss, audiology, audiologist, hearing screening, hearing aids, cochlear implants, tele-audiology, communication access, assistive technology, speech-language pathology, deafness, hard of hearing, public health, kupuna, keiki, dementia, cognitive decline, fall prevention, State Health Planning and Development Agency

Transcript Highlights:

• Schedule II drugs.
• Schedule II drugs.
• Schedule II drugs.
• One and Schedule II drugs.
• I and Schedule II drugs.

Keywords: 1191, senate, all

Transcript Highlights:

• So labeling it marijuana, though, federally, it still will go under a Schedule I drug, correct? No.
• I drug.
• Marijuana, which is still a Schedule I drug. I understand your concerns. I appreciate those.
• And that's still Schedule 1. So I, I understand. for that. And that's still Schedule 1.
• 3 from Schedule 1.

Keywords: 959, house, all

Summary: The Committee on Crime and Public Safety heard House Bill 2641, sponsored by Rep. Hinman, which would create the Intoxicating Cannabinoid Control Act and align Missouri law with recent federal changes affecting intoxicating hemp-derived products. Hinman said the bill is intended to keep products away from children, ensure testing and safety, prevent state agencies from sharing certain cannabis-related information with the federal government, and place enforcement authority primarily with the attorney general and coordinated state and local law enforcement. Committee members questioned why the bill labels intoxicating hemp-derived products as marijuana, how it would affect existing hemp businesses, and whether it should instead create a separate regulatory structure. Hinman and supporters said the bill mirrors federal law and is meant to close loopholes and improve enforcement. Supporters included a trade representative for convenience stores and gas stations, who said retailers want to sell only federally lawful products with age-gating, labeling, and packaging rules, and argued the bill’s reverse-trigger language would keep Missouri aligned with federal law. A law enforcement coalition also supported the bill, citing child-access concerns, hospitalizations, and examples of highly potent gummies and candy-like packaging being sold without adequate oversight. Opponents, including the Missouri Beer Wholesalers Association and hemp business owners, argued the bill would eliminate a lawful industry, push sales into unregulated markets, and force compliant small businesses to close. They urged the committee to adopt a separate regulatory framework for hemp-derived intoxicating products rather than tying them to the marijuana dispensary system. No vote was taken in the hearing.

Transcript Highlights:

• the cost, but in the growth in total of drugs... ...certainly more in specialty drugs, in the cost,
• but in the growth in total of drugs.
• Additionally, I think, you know, the thing to note is with drugs... ...with drugs historically, I think
• Did you actually call people that you had scheduled on-call?
• This isn't some drug that people can optionally take.

Summary: The Assembly Health Committee heard several bills focused on health care access, oversight, and affordability. The first major item was SB 306 by Senator Becker, a prior authorization reform bill. Becker and supporters, including the California Medical Association and California Hospital Association, argued that prior authorization delays care, adds administrative burden, and can lead to serious patient harm. The bill was substantially amended late in the process to have DMHC and CDI identify services and drugs to exempt from prior authorization based on utilization data, with safeguards for fraud, waste, abuse, and patient safety. Health plans and insurers opposed the measure as written, saying prior authorization remains an important utilization-management tool and raising concerns about the 90% threshold, drug inclusion, and how modifications are counted. The committee also heard SB 35 by Senator Umberg, which would let cities or counties inspect unlicensed sober living homes if DHCS does not act promptly on complaints. Supporters said the bill would address weak enforcement and protect residents, while one behavioral health directors group opposed it unless amended. Members generally supported the measure, citing problems with unlicensed facilities and the need for local enforcement backup. The committee then heard SB 62, which would codify California’s updated essential health benefits benchmark if approved by the federal government. Senator Wiener said the package would add hearing aids, durable medical equipment, and infertility treatment including IVF, acknowledging that premiums could rise but arguing the benefits were worth it. Health Access California and other advocates supported the bill, while the California Family Council opposed it. The committee also took up SB 596 by Senator Menjivar, which would tighten the rules for hospitals claiming an on-call list as a defense to nurse staffing ratio penalties. Supporters, including nurses and SEIU, said hospitals have used vague or ineffective on-call practices to avoid accountability and that the bill would improve enforcement and patient safety. Hospital groups opposed it, arguing that staffing is highly dynamic, that hospitals need flexibility to manage acuity and emergencies, and that the bill could increase costs and interfere with collective bargaining arrangements. Finally, the committee heard SB 40 by Senator Wiener, the Insulin Affordability Act, which would cap insulin copays at $35 for a 30-day supply and restrict step therapy unless a plan covers at least one insulin in each drug type. Supporters, including physicians, diabetes advocates, nurses, students, and patient groups, said insulin is life-saving and too often unaffordable, forcing patients to ration or choose between medication and basic needs. There was no formal opposition testimony, though one member questioned why insulin remains so expensive. The committee also began discussion of SB 363, but the transcript cuts off before that bill’s full presentation or any action on the measures. No votes are recorded in the portion provided, and several bills were noted as consent items earlier in the hearing.